Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $19.59M by Medicaid between Jan 2018 and Dec 2024, across 232 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 17% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BRONX, NY 10454
BRONX, NY 10454
33aNPI1134137375assigned 08/03/2006
33bProvider typeInternal Medicine Physician
28Total paid$19.59M
24GClaims582,874
24DCodes billed232
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#15 of 6,049
Median peer was paid$11K
This provider vs. median1,732×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,604 | $34K | |
| 2019 | 32,062 | $1.14M | |
| 2020 | 106,198 | $3.89M | |
| 2021 | 157,754 | $5.37M | |
| 2022 | 105,344 | $3.80M | |
| 2023 | 87,553 | $2.88M | |
| 2024incomplete | 91,359 | $2.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 43,670 | 34,290 | $3.24M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.5% | 19,858 | 15,278 | $1.27M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.7% | 11,211 | 9,112 | $1.11M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.5% | 19,641 | 16,336 | $1.07M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.3% | 6,831 | 5,976 | $654K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.1% | 5,367 | 4,958 | $606K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.0% | 1,422 | 1,402 | $589K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.9% | 22,101 | 14,701 | $578K |
| 86480 | 2.9% | 8,828 | 8,655 | $560K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.8% | 6,138 | 5,157 | $549K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 12,938 | 12,552 | $414K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.9% | 9,199 | 9,144 | $373K |
220 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.6% | 4,300 | $311K |
| 97802 | 1.5% | 6,963 | $299K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.5% | 15,516 | $298K |
| D0999 | Unspecified diagnostic procedure, by report | 1.5% | 1,809 | $289K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.3% | 3,727 | $247K |
| 99443 | 1.2% | 2,708 | $233K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 6,036 | $232K |
| 99442 | 1.2% | 3,281 | $231K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 11,286 | $226K |
| 90461 | 1.1% | 4,127 | $218K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 1,663 | $211K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.0% | 1,575 | $198K |
| 99201 | <1% | 2,968 | $192K | |
| 99441 | <1% | 3,581 | $187K | |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 1,267 | $180K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,235 | $180K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,445 | $173K |
| 80053 | Comprehensive metabolic panel | <1% | 17,612 | $172K |
| 80061 | Lipid panel | <1% | 13,607 | $154K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,769 | $147K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 867 | $146K |
| 86703 | <1% | 9,914 | $139K | |
| 81001 | <1% | 28,294 | $124K | |
| 85027 | <1% | 21,080 | $119K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,372 | $116K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,795 | $113K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 3,129 | $111K |
| 86769 | <1% | 4,183 | $110K | |
| 92558 | <1% | 8,149 | $109K | |
| 90677 | <1% | 574 | $104K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,931 | $102K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,896 | $96K |
| 86780 | <1% | 6,814 | $89K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,174 | $86K |
| 11721 | <1% | 2,596 | $84K | |
| 90686 | <1% | 6,435 | $83K | |
| H0049 | Alcohol and/or drug screening | <1% | 1,668 | $81K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 580 | $80K |
| 87486 | <1% | 3,185 | $78K | |
| 0012A | <1% | 1,980 | $76K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,068 | $75K |
| 90746 | <1% | 1,218 | $72K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,493 | $72K |
| 96127 | <1% | 11,078 | $70K | |
| 90651 | <1% | 1,052 | $69K | |
| 0011A | <1% | 2,086 | $66K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 2,071 | $65K |
| 94760 | <1% | 8,962 | $64K | |
| 83655 | <1% | 4,691 | $62K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 351 | $54K |
| 87581 | <1% | 1,452 | $50K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 2,471 | $49K |
| 0064A | <1% | 1,167 | $48K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,457 | $48K |
| 86803 | <1% | 3,372 | $43K | |
| 81025 | <1% | 4,475 | $43K | |
| 92551 | <1% | 2,445 | $40K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 86 | $39K |
| 3074F | <1% | 12,397 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,698 | $36K |
| 86706 | <1% | 3,421 | $35K | |
| 90715 | <1% | 1,371 | $35K | |
| 90620 | <1% | 735 | $34K | |
| 99051 | <1% | 1,528 | $34K | |
| 87340 | <1% | 3,210 | $33K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,358 | $32K |
| 86762 | <1% | 2,020 | $29K | |
| 88142 | <1% | 1,146 | $26K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 180 | $25K |
| 99406 | <1% | 1,446 | $24K | |
| 86765 | <1% | 1,845 | $23K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 651 | $23K |
| 99381 | <1% | 208 | $23K | |
| 86787 | <1% | 2,013 | $23K | |
| 97803 | <1% | 400 | $22K | |
| 92250 | <1% | 496 | $21K | |
| 86735 | <1% | 1,831 | $21K | |
| 82728 | <1% | 1,595 | $21K | |
| 82948 | <1% | 2,042 | $20K | |
| 99173 | <1% | 4,052 | $20K | |
| 99383 | <1% | 161 | $19K | |
| 92015 | Determination of refractive state | <1% | 724 | $18K |
| 99385 | <1% | 119 | $16K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 776 | $16K |
| 80076 | <1% | 1,954 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,053 | $16K |
| 87800 | <1% | 422 | $16K | |
| 83550 | <1% | 2,001 | $15K | |
| 90732 | <1% | 118 | $14K | |
| 90674 | <1% | 613 | $14K | |
| 81408 | <1% | 14 | $13K | |
| 83540 | <1% | 2,150 | $13K | |
| 90714 | <1% | 524 | $12K | |
| 76801 | <1% | 87 | $11K | |
| 84702 | <1% | 785 | $11K | |
| D0120 | Dental checkup, returning patient | <1% | 1,251 | $10K |
| 84439 | <1% | 1,136 | $10K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,032 | $9K |
| 90670 | <1% | 815 | $9K | |
| 0134A | <1% | 209 | $9K | |
| 87081 | <1% | 1,299 | $9K | |
| 99384 | <1% | 67 | $9K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 312 | $9K |
| 90480 | <1% | 187 | $8K | |
| 90707 | <1% | 201 | $7K | |
| 83020 | <1% | 519 | $7K | |
| D0274 | Bitewings - four radiographic images | <1% | 875 | $6K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 116 | $6K |
| 85045 | <1% | 1,534 | $6K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 44 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 121 | $6K |
| 96161 | <1% | 886 | $6K | |
| 90656 | <1% | 513 | $6K | |
| 91322 | <1% | 86 | $6K | |
| 86708 | <1% | 462 | $6K | |
| 82043 | <1% | 1,090 | $6K | |
| 86580 | <1% | 414 | $5K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 329 | $5K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 42 | $5K |
| G0467 | Community health center visit, returning patient | <1% | 1,635 | $5K |
| 82607 | <1% | 326 | $5K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,235 | $4K |
| 90697 | <1% | 33 | $4K | |
| 86850 | <1% | 295 | $4K | |
| 90734 | <1% | 579 | $4K | |
| D4341 | <1% | 239 | $4K | |
| 90716 | <1% | 103 | $4K | |
| D1110 | Prophylaxis - adult | <1% | 406 | $4K |
| 0072A | <1% | 78 | $4K | |
| 0071A | <1% | 77 | $4K | |
| 90633 | <1% | 479 | $3K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 320 | $3K |
| 0124A | <1% | 56 | $3K | |
| 86592 | <1% | 493 | $3K | |
| 99382 | <1% | 266 | $3K | |
| 81161 | <1% | 14 | $3K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 532 | $2K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 701 | $2K |
| 84460 | <1% | 451 | $2K | |
| D1120 | Dental cleaning, child | <1% | 238 | $2K |
| 86901 | <1% | 342 | $2K | |
| 90662 | <1% | 102 | $2K | |
| 90698 | <1% | 295 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 267 | $2K |
| 81003 | <1% | 885 | $2K | |
| 82248 | <1% | 384 | $2K | |
| 86900 | <1% | 338 | $2K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 823 | $2K |
| 86003 | <1% | 75 | $2K | |
| 84450 | <1% | 433 | $2K | |
| D0191 | <1% | 315 | $2K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 27 | $2K |
| 81405 | <1% | 12 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $2K |
| 82274 | <1% | 140 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 44 | $2K |
| 90474 | <1% | 111 | $2K | |
| 86704 | <1% | 139 | $2K | |
| D0330 | Panoramic radiographic image | <1% | 146 | $2K |
| 0004A | <1% | 31 | $1K | |
| 11056 | <1% | 17 | $1K | |
| D1330 | <1% | 1,053 | $1K | |
| 84703 | <1% | 251 | $1K | |
| 90680 | <1% | 230 | $1K | |
| 81361 | <1% | 14 | $1K | |
| 90473 | <1% | 61 | $1K | |
| 90661 | <1% | 45 | $998.26 | |
| 90710 | <1% | 64 | $947.22 | |
| 90672 | <1% | 156 | $922.68 | |
| 81401 | <1% | 14 | $904.20 | |
| 81257 | <1% | 15 | $872.10 | |
| D1351 | Sealant - per tooth | <1% | 113 | $837.48 |
| D1206 | Topical application of fluoride varnish | <1% | 105 | $781.15 |
| 90694 | <1% | 27 | $753.19 | |
| 90653 | <1% | 41 | $751.17 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12 | $739.63 |
| 72100 | <1% | 16 | $693.10 | |
| 0074A | <1% | 15 | $677.35 | |
| 82785 | <1% | 48 | $653.92 | |
| 81243 | <1% | 14 | $593.19 | |
| 81255 | <1% | 14 | $535.11 | |
| 82947 | <1% | 126 | $492.93 | |
| 81200 | <1% | 14 | $491.43 | |
| 81251 | <1% | 14 | $491.43 | |
| 82951 | <1% | 43 | $427.59 | |
| 81400 | <1% | 14 | $422.16 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 758 | $420.31 |
| 81260 | <1% | 14 | $408.82 | |
| 83525 | <1% | 34 | $396.54 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 32 | $375.53 |
| 82746 | <1% | 27 | $373.62 | |
| 90744 | <1% | 43 | $368.91 | |
| 87177 | <1% | 36 | $341.49 | |
| 82105 | <1% | 24 | $310.30 | |
| 90696 | <1% | 50 | $284.30 | |
| 86593 | <1% | 61 | $282.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14 | $167.38 |
| D0210 | Intraoral - complete series of radiographic images | <1% | 33 | $151.58 |
| 90648 | <1% | 25 | $143.18 | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 13 | $135.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41 | $123.63 |
| 87186 | <1% | 15 | $118.63 | |
| 87338 | <1% | 12 | $117.33 | |
| 81015 | <1% | 24 | $85.99 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 35 | $59.50 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 46 | $29.12 |
| 3077F | 0% | 612 | $0.00 | |
| 3078F | 0% | 9,488 | $0.00 | |
| 99499 | 0% | 586 | $0.00 | |
| 1160F | 0% | 15 | $0.00 | |
| 1159F | 0% | 21 | $0.00 | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | 0% | 12 | $0.00 |
| 3075F | 0% | 1,588 | $0.00 | |
| 3079F | 0% | 1,938 | $0.00 | |
| 3080F | 0% | 146 | $0.00 | |
| D1310 | 0% | 87 | $0.00 | |
| 1220F | 0% | 988 | $0.00 | |
| D0602 | 0% | 14 | $0.00 | |
| D0601 | 0% | 36 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.